Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

George A. Boswell, Hui Yin Li, Indawari Delucca, Jeffrey T. Billheimer, Spencer Drummond, Peter J. Gillies, Candy Robinson

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. Compound 6 and its R-enantiomer 6a exhibited very potent oral activities in lowering the serum cholesterol in the animals.

Original languageEnglish (US)
Pages (from-to)885-888
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume6
Issue number7
DOIs
StatePublished - Apr 9 1996
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this